向Regnase-1释放了对骨髓瘤的CAR T细胞抗瘤活性,并创造了一个促炎性瘤微环境
Adeleye O Adeshakin1, Hao Shi2, S Scott Perry1
1Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.
bioRxiv : the preprint server for biology
|June 6, 2025
概括
删除CAR T细胞中的Regnase-1增强了它们的抗瘤活性,并促进了促炎性瘤微环境. 这种方法通过重塑免疫环境,改善了对固体瘤的CAR T细胞疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 细胞疗法细胞疗法
背景情况:
- 对T细胞功能的负调节者是加强对固体瘤的CAR T细胞治疗的目标.
- 免疫抑制性瘤微环境对CAR T细胞的疗效构成障碍.
- 删除负调节因子对瘤免疫格局的影响尚不清楚.
研究的目的:
- 研究删除B7-H3 CAR T细胞中的Regnase-1 (Reg-1) 的影响.
- 为了确定CAR T细胞中的Reg-1删除是否可以克服免疫抑制瘤微环境.
- 评估Reg-1删除对CAR T细胞功能和瘤免疫格局的内在和外在影响.
主要方法:
- 针对B7-H3.3的CAR T细胞的开发
- 在CAR T细胞中删除负调节剂Regnase-1 (Reg-1).
- 在具有免疫能力的骨髓瘤模型中评估CAR T细胞效应因子功能.
- 对瘤微环境组成和细胞因子生产的分析.
主要成果:
- 删除Reg-1改善了B7-H3 CAR T细胞的内在效应器功能.
- 删除Reg-1促进了促炎性瘤微环境.
- 有Reg-1删除的CAR T细胞诱导了IFNγ产生T细胞和NK细胞的涌入.
- 删除Reg-1导致抑制性髓状细胞的减少,包括M2巨细胞.
结论:
- 在CAR T细胞中删除像Reg-1这样的负调节剂可以增强它们的抗瘤活性.
- 设计为缺乏Reg-1的CAR-T细胞可以将瘤微环境重新编程到一种促炎状态.
- 这种策略强制执行非细胞自主效应,改善固体瘤的CAR T细胞治疗.
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


